Annexin A3 in Urine: A Highly Specific Noninvasive Marker for Prostate Cancer Early Detection

Journal of Urology

Volumn 181, Issue 1, 2009, Pages 343-353

  Schostak, Martin ^a   Schwall, Gerhard P ^b   Poznanović, Slobodan ^b   Groebe, Karlfried ^b   Müller, Markus ^c   Messinger, Diethelm ^d   Miller, Kurt ^a   Krause, Hans ^a   Pelzer, Alexandre ^f   Horninger, Wolfgang ^f   Klocker, Helmut ^f   Hennenlotter, Jörg ^e   Feyerabend, Susan ^e   Stenzl, Arnulf ^b   Schrattenholz, André ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b PROTEOSYS AG   (Germany)

^c KLINIKUM LUDWIGSHAFEN   (Germany)

^d IST GmbH   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

annexin A; biological; prostate; prostate specific antigen; prostatic neoplasms; tumor markers

Indexed keywords

GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN URINE LEVEL; URINALYSIS; WESTERN BLOTTING;

ANNEXIN A3; BIOLOGICAL MARKERS; EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 57249095672     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.08.119     Document Type: Article

References (20)

1. Roddam A.W., Duffy M.J., Hamdy F.C., Ward A.M., Patnick J., Price C.P., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48 (2005) 386
2. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297
3. Lilja H., Ulmert D., and Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8 (2008) 268
4. Reynolds M.A., Kastury K., Groskopf J., Schalken J.A., and Rittenhouse H. Molecular markers for prostate cancer. Cancer Lett 249 (2007) 5
5. Gerke V., Creutz C.E., and Moss S.E. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6 (2005) 449
6. Xin W., Rhodes D.R., Ingold C., Chinnaiyan A.M., and Rubin M.A. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol 162 (2003) 255
7. Wozny W., Schroer K., Schwall G., Poznanovic S., Stegmann W., Dietz K., et al. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics 7 (2007) 313
8. Köllermann J., Schlomm T., Bang H., Schwall G.P., von Eichel-Streiber C., Simon R., et al. Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol 54 (2008) 1314
9. Pisitkun T., Shen R.F., and Knepper M.A. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 101 (2004) 13368
10. Carlsson L., Larsson A., Ronquist G., and Nilsson B.O. Prostasome antigens as targets for sperm agglutinating antibodies demonstrated by 1-D gel electrophoresis and immunoblottings. Int J Androl 27 (2004) 360
11. Goessl C., Muller M., Heicappell R., Krause H., Straub B., Schrader M., et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58 (2001) 335
12. Chen M.E., Troncoso P., Johnston D.A., Tang K., and Babaian R.J. Optimization of prostate biopsy strategy using computer based analysis. J Urol 158 (1997) 2168
13. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587
14. Ohkia A., Hu Y., Wang M., Garcia F.U., and Stearns M.E. Evidence for prostate cancer-associated diagnostic marker-1: immunohistochemistry and in situ hybridization studies. Clin Cancer Res 10 (2004) 2452
15. Leman E.S., Cannon G.W., Trock B.J., Sokoll L.J., Chan D.W., Mangold L., et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69 (2007) 714
16. Djavan B., Ravery V., Zlotta A., Dobronski P., Dobrovits M., Fakhari M., et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol 166 (2001) 1679
17. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283
18. Minelli A., Ronquist G., Carlsson L., Mearini E., Nilsson O., and Larsson A. Antiprostasome antibody titres in benign and malignant prostate disease. Anticancer Res 25 (2005) 4399
19. Park J.E., Lee D.H., Lee J.A., Park S.G., Kim N.S., Park B.C., et al. Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun 337 (2005) 1283
20. Madoz-Gurpide J., Lopez-Serra P., Martinez-Torrecuadrada J.L., Sanchez L., Lombardia L., and Casal J.I. Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol Cell Proteomics 5 (2006) 1471